^
    1d
    Combining Sodium Valproate With Standard-of-care EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibody Treatment in Patients With Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2, N=38, Active, not recruiting, Australasian Gastro-Intestinal Trials Group | Recruiting --> Active, not recruiting | N=90 --> 38 | Trial primary completion date: Apr 2026 --> Jan 2026
    Enrollment closed • Enrollment change • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    KRAS wild-type • RAS wild-type
    |
    Erbitux (cetuximab) • Vectibix (panitumumab)
    2d
    Structure evaluation coupled with all-atom molecular dynamics and advanced quantum mechanical DFT revealed kaempferol as a potent binding flavonol for the epigenetic-target HDAC9. (PubMed, J Biosci)
    Similar to givinostat, kaempferol exhibited tenable stability in bound form with this acetylation-eraser enzymatic protein. Most importantly, this flavonol demonstrated higher chemical reactivity and, as such, lower kinetic stability than givinostat which is quite important from a pharmacological perspective.
    Journal
    |
    HDAC9 (Histone Deacetylase 9)
    |
    Duvyzat (givinostat)
    3d
    Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas (clinicaltrials.gov)
    P1, N=83, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Apr 2026 --> Apr 2027
    Trial completion date
    |
    temozolomide • Zolinza (vorinostat)
    3d
    RESOLVE: Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in Urothelial Carcinoma (clinicaltrials.gov)
    P1, N=9, Active, not recruiting, University of Utah | Trial primary completion date: Apr 2026 --> Aug 2026
    Trial primary completion date
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • Beleodaq (belinostat)
    4d
    Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL) (clinicaltrials.gov)
    P1/2, N=11, Terminated, University of Michigan Rogel Cancer Center | Active, not recruiting --> Terminated; Lack of accrual
    Trial termination
    |
    Ninlaro (ixazomib) • Istodax (romidepsin)
    4d
    Chidamide Combined With Chemotherapy and Immunotherapy as First-line Treatment for Advanced Intrahepatic Cholangiocarcinoma (clinicaltrials.gov)
    P2, N=35, Recruiting, Shanghai Zhongshan Hospital
    New P2 trial • IO biomarker
    |
    cisplatin • gemcitabine • Epidaza (chidamide)
    6d
    An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab (clinicaltrials.gov)
    P1/2, N=35, Recruiting, National Institute of Allergy and Infectious Diseases (NIAID) | Trial completion date: Jun 2026 --> Jun 2035 | Trial primary completion date: Jun 2026 --> Jun 2035
    Trial completion date • Trial primary completion date
    |
    IL23A (Interleukin 23 Subunit Alpha)
    |
    Zolinza (vorinostat)
    7d
    Synergistic antitumor effect between Olaparib and Chidamide by regulation of MYBL2 in lung cancer. (PubMed, Anticancer Drugs)
    On the other hand, MYBL2 may regulate the expression of cycle protein dependent kinase 1, causing G2M cell cycle arrest. Consequently, the combination of Olaparib and Chidamide synergistically induces cell apoptosis through synthetic lethality and cell cycle arrest to exert an antitumor effect.
    Journal • BRCA Biomarker • PARP Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • MYBL2 (MYB Proto-Oncogene Like 2)
    |
    Lynparza (olaparib) • Epidaza (chidamide)
    7d
    Long-Term Follow-Up of Chidamide With Chemotherapy in Untreated Peripheral T-Cell Lymphoma: One Single Center Real-World Study in China. (PubMed, Hematol Oncol)
    The identification of gene mutations contributed to personalizing treatment strategies and predicting patient outcomes. This study raised the preliminary hypothesis that chidamide-containing front-line therapy might be promising for PTCL patients, which warranted further investigation.
    Journal • Real-world evidence
    |
    TP53 (Tumor protein P53) • DNMT3A (DNA methyltransferase 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • RHOA (Ras homolog family member A)
    |
    TP53 mutation • TET2 mutation
    |
    Epidaza (chidamide)
    8d
    HDAC inhibition unlocks tumor plasticity and enhances immunotherapy response in Myc-driven small cell lung cancer. (PubMed, Mol Cancer Ther)
    In vivo, we confirmed that entinostat treatment increased the expression of immunecheckpoint ligands and antigen presentation machinery in Myc-driven tumors in a Rb1/Trp53/MycT58A (RPM) SCLC mouse model, while shifting tumors from a neuroendocrine (NE)-high to a NE-low phenotype, and was associated with increased T-cell infiltration Notably, combining entinostat with anti-PD-1 immunotherapy suppresses tumor growth and significantly prolonged survival in RPM allograft models. These findings underscore the potential of entinostat to reprogram the NE status of SCLC, enhance immune checkpoint blockade efficacy, and improve therapeutic outcomes.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    TP53 (Tumor protein P53) • RB1 (RB Transcriptional Corepressor 1)
    |
    Jingzhuda (entinostat)
    9d
    Nobiletin inhibits non-small cell lung cancer through TRKC and exhibits a synergistic effect with the HDAC inhibitor. (PubMed, Chin J Nat Med)
    Eukaryotic transcriptome sequencing revealed that the combination treatment primarily inhibits tumor cell proliferation by modulating TRKC protein expression and suppressing phosphorylation of the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) signaling pathway. Therefore, our results indicate that nobiletin, a natural BH3 mimetic, synergizes with vorinostat to regulate both apoptosis and autophagy in NSCLC.
    Journal • PARP Biomarker • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • MCL1 (Myeloid cell leukemia 1) • CASP3 (Caspase 3) • BECN1 (Beclin 1) • MAP1LC3A (Microtubule Associated Protein 1 Light Chain 3 Alpha)
    |
    Zolinza (vorinostat)
    10d
    SWOG-S1117: Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia (clinicaltrials.gov)
    P2, N=282, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Mar 2027
    Trial completion date
    |
    lenalidomide • azacitidine • Zolinza (vorinostat)